

Bibliographical References of Molecular Interactions

- $S \rightarrow \text{ATM}$ [1, 2]
- $S \rightarrow \text{ATR}$ [1, 2]
- $\text{ATM} \dashv \text{Cdc25}$ [3, 4] (*)
- $\text{ATR} \dashv \text{Cdc25}$ [4]
- $\text{ATM} \rightarrow \text{p53}$ [5, 6]
- $\text{ATM} \dashv \text{Mdm2}$ [2, 7]
- $\text{ATM} \rightarrow \text{E2F1}$ [8]
- $\text{ATR} \rightarrow \text{E2F1}$ [8]
- $\text{ATR} \rightarrow \text{p53}$ [9]
- $\text{Wip1} \dashv \text{p53}$ [10]
- $\text{Wip1} \dashv \text{Mdm2}$ [11]
- $\text{Wip1} \dashv \text{ATM}$ [12]
- $\text{Mdm2} \dashv \text{p53}$ [13, 14, 15]
- $\text{Mdm2} \dashv \text{p21}$ [16]
- $\text{Mdm2} \dashv \text{pRB}$ [17, 18]
- $\text{p53} \rightarrow \text{Mdm2}$ [19, 13, 15]
- $\text{p53} \rightarrow \text{p21}$ [20, 21]
- $\text{p53} \rightarrow \text{Wip1}$ [22]
- $\text{p53} \rightarrow \text{miR16}$ [23]
- $\text{E2F1} \rightarrow \text{p53}$ [24]
- $\text{E2F1} \rightarrow \text{ATM}$ [25]
- $\text{E2F1} \rightarrow \text{miR16}$ [26]
- $\text{p21} \dashv \text{Cdk2cE}$ [27]
- $\text{p21} \dashv \text{Cdk46cD}$ [27]
- $\text{pRB} \dashv \text{E2F1}$ [28]
- $\text{pRB} \rightarrow \text{Mdm2}$ [29]

- miR16 \dashv Cdk2cE [30]
- miR16 \dashv Cdk46cD [30]
- miR16 \dashv Wip1 [31]
- Cdc25 \rightarrow Cdk2cE [32]
- Cdk2cE \dashv pRB [33]
- Cdk46cD \dashv pRB [34]

References

- [1] Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes & Development*. 2001;15(17):2177–2196. doi:10.1101/gad.914401.
- [2] Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. *Proceedings of the National Academy of Sciences*. 1999;96(26):14973–14977. doi:10.1073/pnas.96.26.14973.
- [3] Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. *Nature*. 2001;410(6830):842–847. doi:10.1038/35071124.
- [4] Thanasoula M, Escandell JM, Suwaki N, Tarsounas M. ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres. *The EMBO Journal*. 2012;31(16):3398–3410. doi:10.1038/emboj.2012.191.
- [5] Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, et al. Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage. *Science*. 1998;281(5383):1674–1677. doi:10.1126/science.281.5383.1674.
- [6] Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53. *Science*. 1998;281(5383):1677–1679. doi:10.1126/science.281.5383.1677.
- [7] Maya R, Balass M, Kim ST, Shkedy D, Leal JFM, Shifman O, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. *Genes & development*. 2001;15(9):1067–1077.
- [8] Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. *Genes & Development*. 2001;15(14):1833–1844.

- [9] Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. *Genes & Development*. 1999;13(2):152–157.
- [10] Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, et al. p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. *The EMBO Journal*. 2000;19(23):6517–6526. doi:10.1093/emboj/19.23.6517.
- [11] Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 Phosphatase Acts as a Gatekeeper in the p53-Mdm2 Autoregulatory Loop. *Cancer Cell*. 2007;12(4):342–354. doi:https://doi.org/10.1016/j.ccr.2007.08.033.
- [12] Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, et al. Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways. *Molecular Cell*. 2006;23(5):757–764. doi:https://doi.org/10.1016/j.molcel.2006.07.010.
- [13] Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. *Cellular and Molecular Life Sciences CMLS*. 1999;55(1):96–107. doi:10.1007/s000180050273.
- [14] Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. *Nature*. 1997;387(6630). doi:http://dx.doi.org/10.1038/387296a0.
- [15] Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. *Genes & Development*. 1993;7(7a):1126–1132. doi:10.1101/gad.7.7a.1126.
- [16] Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53. *Journal of Biological Chemistry*. 2004;279(16):16000–16006. doi:10.1074/jbc.M312264200.
- [17] Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S, et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. *The EMBO Journal*. 2004;24(1):160–169. doi:10.1038/sj.emboj.7600486.
- [18] Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. *Nature*. 1995;375(6533):694–698. doi:10.1038/375694a0.
- [19] Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. *The EMBO Journal*. 1993;12.
- [20] Duli V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. *Cell*. 1994;76(6):1013–1023. doi:http://dx.doi.org/10.1016/0092-8674(94)90379-4.

- [21] El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 Is Induced in p53-mediated G1 Arrest and Apoptosis. *Cancer Research*. 1994;54(5):1169–1174.
- [22] Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. *Proceedings of the National Academy of Sciences*. 1997;94(12):6048–6053.
- [23] Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. *Nature*. 2009;460(7254):529–533. doi:10.1038/nature08199.
- [24] Polager S, Ginsberg D. p53 and E2f: partners in life and death. *Nat Rev Cancer*. 2009;9(10):738–748. doi:10.1038/nrc2718.
- [25] Berkovich E, Ginsberg D. ATM is a target for positive regulation by E2F-1. *Oncogene*. 2003;22(2):161–167. doi:10.1038/sj.onc.1206144.
- [26] Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*. 2011;1812(5):592–601. doi:https://doi.org/10.1016/j.bbadis.2011.02.002.
- [27] Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, et al. Inhibition of cyclin-dependent kinases by p21. *Molecular Biology of the Cell*. 1995;6(4):387–400. doi:10.1091/mbc.6.4.387.
- [28] Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. *Cell*. 1991;65(6):1053–1061. doi:http://dx.doi.org/10.1016/0092-8674(91)90557-F.
- [29] Hsieh JK, Chan FSG, O'Connor DJ, Mittnacht S, Zhong S, Lu X. RB Regulates the Stability and the Apoptotic Function of p53 via MDM2. *Molecular Cell*. 1999;3(2):181–193. doi:http://dx.doi.org/10.1016/S1097-2765(00)80309-3.
- [30] Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. *Nucleic Acids Research*. 2008;36(16):5391–5404. doi:10.1093/nar/gkn522.
- [31] Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, et al. Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling Pathway. *Cancer Research*. 2010;70(18):7176–7186. doi:10.1158/0008-5472.CAN-10-0697.
- [32] Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. *EMBO reports*. 2003;4(7):671–677. doi:10.1038/sj.embor.embor887.

- [33] Takaki T, Fukasawa K, Suzuki-Takahashi I, Hirai H. Cdk-mediated phosphorylation of pRB regulates HDAC binding in vitro. *Biochemical and Biophysical Research Communications*. 2004;316(1):252–255. doi:<http://dx.doi.org/10.1016/j.bbrc.2004.02.044>.
- [34] Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK)4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. *Discovery medicine*. 2016;21(113):65–74.